HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

CXCL8 and its cognate receptors in melanoma progression and metastasis.

Abstract
The incidence of melanoma is rising at an alarming rate and we are still awaiting an effective treatment for this malignancy. In its early stage, melanoma can be cured by surgical removal, but once metastasis has occurred there is no effective treatment. Recent findings have suggested multiple functional implications of CXCL8 and its cognate receptors, CXCR1 and CXCR2, in melanoma pathogenesis, thus underscoring their importance as targets for cancer therapy. This review provides an update on the roles of CXCL8 and its receptors in melanoma progression and metastasis.
AuthorsSeema Singh, Ajay P Singh, Bhawna Sharma, Laurie B Owen, Rakesh K Singh
JournalFuture oncology (London, England) (Future Oncol) Vol. 6 Issue 1 Pg. 111-6 (Jan 2010) ISSN: 1744-8301 [Electronic] England
PMID20021212 (Publication Type: Journal Article, Review)
Chemical References
  • Interleukin-8
  • Receptors, Interleukin-8A
  • Receptors, Interleukin-8B
Topics
  • Animals
  • Disease Progression
  • Humans
  • Interleukin-8 (metabolism)
  • Melanoma (metabolism, pathology)
  • Neoplasm Metastasis (pathology)
  • Receptors, Interleukin-8A (metabolism)
  • Receptors, Interleukin-8B (metabolism)
  • Skin Neoplasms (metabolism, pathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: